These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38288881)

  • 21. Molnupiravir for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):10-11. PubMed ID: 35134041
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 23. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
    Khiali S; Khani E; B Rouy S; Entezari-Maleki T
    Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.
    Amani B; Zareei S; Amani B
    Br J Clin Pharmacol; 2022 Oct; 88(10):4403-4411. PubMed ID: 35762036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
    Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
    Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
    Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C
    Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
    Johnson MG; Strizki JM; Brown ML; Wan H; Shamsuddin HH; Ramgopal M; Florescu DF; Delobel P; Khaertynova I; Flores JF; Fouche LF; Chang SC; Williams-Diaz A; Du J; Grobler JA; Paschke A; De Anda C
    Infection; 2023 Oct; 51(5):1273-1284. PubMed ID: 36648627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).
    Johnson MG; Strizki JM; Jensen E; Cohen J; Katlama C; Fishchuk R; Ponce-de-León A; Fourie N; Cheng C-Y; McCoy D; Vesnesky M; Norice CT; Zhang Y; Williams-Diaz A; Brown ML; Carmelitano P; Grobler JA; Paschke A; De Anda C
    Microbiol Spectr; 2024 Mar; 12(3):e0356323. PubMed ID: 38299867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molnupiravir for the Treatment of Coronavirus Disease 2019: A Systematic Review With Meta-Analysis of 12,451 Patients.
    Beran A; Mhanna A; Mhanna M; Farrow D; Sidiki S; Khader Y; Srour O; Kayyali A
    Am J Ther; 2024 Jan-Feb 01; 31(1):e47-e50. PubMed ID: 38231582
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
    Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
    Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
    Parums DV
    Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
    Kayali F; Leung MST; Wong W; Morgan KP; Harky A
    Expert Opin Pharmacother; 2022 Jun; 23(8):865-868. PubMed ID: 35341442
    [No Abstract]   [Full Text] [Related]  

  • 35. Molnupiravir: Mechanism of action, clinical, and translational science.
    Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA
    Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
    Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
    Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of molnupiravir: A Danish nationwide drug utilization study.
    Ladebo L; Rasmussen L; Jensen PB; Lindahl M; Øvrehus A; Hallas J; Reilev M
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5700. PubMed ID: 37743261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
    Wallace KB; Bjork JA
    Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
    Holman W; Holman W; McIntosh S; Painter W; Painter G; Bush J; Cohen O
    Trials; 2021 Aug; 22(1):561. PubMed ID: 34425873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.